Mark Huth, MD
Cardiovascular Disease · Medford, ORNPI 1669461208
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Astellas Pharma US Inc at 51.0% of the total. Reporting peaked in 2021 at $216 and has fallen 91.1% since, to $19 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in OR, where the typical reported total is $873.
Across 13 payments — averaging $29.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$198
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
- Boston Scientific$61
- Regeneron Healthcare Solutions, Inc.$11
Across 5 payments — averaging $7454.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$21K
- AstraZeneca$10K
- Kowa Research Institute, Inc.$6K
What the payments were for
- Food & beverage$17946%
- Education$20954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $118 |
| Boston Scientific | 3 | $61 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
How this compares
$388 in reported general payments places this provider in the 35th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $434,614 |
| XareltoRivaroxaban | 203 | $269,392 |
| EntrestoSacubitril/Valsartan | 132 | $180,145 |
| JardianceEmpagliflozin | 38 | $43,134 |
| Repatha SureclickEvolocumab | 19 | $27,706 |
| Metoprolol Succinate | 888 | $15,460 |
| Praluent PenAlirocumab | 13 | $11,792 |
| BrilintaTicagrelor | 13 | $8,504 |
| Flecainide Acetate | 91 | $4,557 |
| Losartan Potassium | 303 | $3,369 |
| Digoxin | 138 | $3,169 |
| Carvedilol | 262 | $2,440 |
| Atorvastatin Calcium | 156 | $2,424 |
| Isosorbide Dinitrate | 14 | $2,123 |
| Potassium Chloride | 115 | $1,870 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Medford
- Benjamin SalgadoMedford$3K
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.